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ABSTRACT
Introduction: Erythropoiesis-stimulating agents
and iron are commonly used in patients with
chronic kidney diseasewith the aimof correcting
anemia and maintaining stable hemoglobin
levels. We analyzed pooled data from 13 studies
with similar designs included in the Umbrella
Continuous Erythropoietin Receptor Activator
(C.E.R.A.) program to investigate the effects of
continuous erythropoiesis receptor activator in
clinically relevant subgroups of patients with
chronic kidneydisease and todeterminewhether
the efficacy and safety outcomes demonstrated
in the overall chronic kidney disease population
are maintained in specific subgroups.
Methods: Data from 13 Phase III trials set up
with similar design were retrospectively pooled
for this analysis. Patients with chronic kidney
disease who had previously been receiving
epoetin or darbepoetin were switched to
continuous erythropoiesis receptor activator
once-monthly after a 4- to 8-week screening
period. Patients entered a 16-week continuous
erythropoiesis receptor activator dose-titration
period followed by an 8-week evaluation
period. In total, 2060 patients were included
in the analysis. Subgroups were defined
based on: hemoglobin target range [lower
(10.0–12.0 g/dL)/upper (10.5–13.0 g/dL)], gender
(female/male), age (\65/C65), baseline
N-terminal pro-B-type natriuretic peptide
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levels (\5000/C5000), cardiovascular risk
factors (diabetes/cardiac/vascular/none).
Results: Across all subgroups analyzed,
switching from shorter-acting
erythropoiesis-stimulating agents to
continuous erythropoiesis receptor activator
once-monthly maintained stable hemoglobin
concentrations in a high proportion of patients
(78%), with only moderate hemoglobin
fluctuations and a low number of dose
changes. The safety profile across subgroups
was as expected based on pre-existing risk
factors; observed increases in adverse events
were attributable to underlying risk factors
rather than study drug.
Conclusions: This retrospective analysis of 13
trials showed that continuous erythropoiesis
receptor activator once-monthly maintained
stable hemoglobin levels across a number of
clinically relevant patient subgroups, including
those with higher inherent cardiovascular risk.
The safety profile was consistent with that
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INTRODUCTION
Anemia is common in patients with chronic
kidney disease (CKD); severe anemia can reduce
quality of life, and increase the risk of
cardiovascular (CV) events and mortality [1,
2]. Anemia management is central in care for
patients with CKD, and treatment with iron and
erythropoiesis-stimulating agents (ESAs) is the
standard of care for patients on dialysis.
Therapeutic goals include correcting anemia
and maintaining stable hemoglobin (Hb)
levels. Reduced ESA dose and frequency of
administration should also be sought [3, 4]. A
recent systematic review and meta-analysis of
randomized trials in patients with CKD
analyzed data from more than 12,000 patients
in 40 trials with the aim of comparing the
efficacy and safety of ESAs [5]. The conclusion
was that epoetins (epoetin alfa, epoetin beta;
darbepoetin alfa, methoxy polyethylene
glycol-epoetin beta) were similarly effective for
preventing blood transfusion and better than
placebo and that currently all ESAs are safe and
efficacious with minimal differences between
the different formulations in the CKD setting.
Despite well-defined therapeutic goals,
maintaining Hb within the desired range is
challenging in patients with CKD: many
factors, including iron status and comorbidities,
influence the response to treatment. Continuous
erythropoiesis receptor activator [C.E.R.A.
(methoxy polyethylene glycol-epoetin beta)] [6]
has a long half-life (134 h), a relatively low
binding affinity for the erythropoietin receptor
and low systemic clearance, allowing
once-monthly (QM) dosing, which may be
more convenient for patients compared with
shorter-acting ESAs [6, 7].
A variety of Phase II and III trials of C.E.R.A.
have been conducted in CKD. Data from 13
Phase III trials set up with similar design were
pooled for this analysis, each multicenter study
set up using similar inclusion and exclusion
criteria and trial design to allow analyses to be
performed both at the single-study level and
using pooled data from multiple studies. Data
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from individual studies in dialysis-dependent
patients with CKD have demonstrated that
C.E.R.A. QM maintains stable on-target Hb
concentrations with fewer dose adjustments
than shorter-acting ESAs [7–16]. Pooling data
from similar individual studies allows
investigating the efficacy and safety of C.E.R.A.
in clinically relevant subgroups of patients with
CKD, where underlying risk factors can
potentially affect patients’ response to
treatment.
The present pool comprises 13 similarly
designed studies investigating the efficacy and
safety of C.E.R.A. QM in 2060 dialysis patients.
Studies were conducted in real-life settings
across numerous countries between 2007 and
2011. The aim of this analysis was to determine
whether the efficacy and safety of C.E.R.A. is
affected by CV risk factors, age, gender, or
protocol-defined Hb target ranges.
METHODS
For this analysis, data from 13 interventional,
open-label, multicenter trials included in the






404 centers across Brazil, Czech Republic,
France, Germany, Greece, Hungary, Italy,
Latin America, Morocco, Russia, Spain,
Switzerland and Turkey were pooled
(Supplementary Table 1). Ten single-arm and
three 2-arm randomized trials were run under
an Umbrella protocol to ensure similar
populations and similar treatment regimens.
All patients from the 10 single-arm trials and
patients from the C.E.R.A. arm of the three
randomized trials have been combined for
this Umbrella analysis.
Ethics Statement
Studies were conducted in accordance with the
Declaration of Helsinki of 1964, as revised in
2013, and the protocols were approved by the
Institutional Review Boards/local Independent
Ethics Committees at each center. Written
informed consent was obtained from all
participants. Data analyzed in this manuscript
are from previously published studies.
Subjects, Inclusion and Exclusion Criteria
Inclusion and exclusion criteria were similar
across studies. Patients (C18 years) with
chronic renal anemia on hemodialysis
meeting the following criteria were eligible:
Hb concentration within the study’s target
range, adequate iron status [serum ferritin
[100 ng/mL and transferrin saturation (TSAT)
[20% or hypochromic red cells \10%],
continuous ESA maintenance therapy with
unchanged dosing interval and weekly dose
during the previous month, regular long-term
dialysis with identical mode of dialysis for at
least 3 previous months.
Exclusion criteria were relevant acute
or chronic bleeding, or erythrocyte transfusion
within the preceding 8 weeks,
hemoglobinopathy or known hemolysis, active
malignant disease, vitamin B12 or folic
acid deficiency, pure red cell aplasia, platelet
count [500 9 109/L or \100 9 109/L, poorly
controlled hypertension, myocardial
infarction, stroke, severe/unstable coronary
artery disease, severe liver disease during the
previous 3 months or severe congestive heart
failure (New York Heart Association class IV).
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Study Design
Patients with chronic renal anemia on dialysis
(Table 1) receiving ESA treatment entered a 4- to
8-week screening period, during which mean Hb
concentrations were maintained within the
study’s target range (10–12 or 10.5–13 g/dL).
Patients then entered a 16-week C.E.R.A.
dose-titration period followed by an 8-week
evaluation period (Fig. 1), with Hb
concentrations assessed during screening,
titration and evaluation. Subgroups were
defined based on: Hb target range (lower,
10.0–12.0 g/dL/upper, 10.5–13.0 g/dL); gender
(F/M); age (\65/C65); baseline N-terminal
pro-B-type natriuretic peptide (NT-proBNP)
levels (\5000/C5000, a 5000 ng/mL cut-off was
predictive for various endpoints [17]); CV risk
factors (diabetes/cardiac/vascular/none). Patients
were further subdivided per quintiles of C.E.R.A.
dose (lg: q1 B 70; q2= 70–110; q3= 110–125;
q4= 125–185; q5 C 185), Hb (g/dL: q1 B 10.65;
q2= 10.65–11.2; q3= 11.2–11.7; q4 = 11.7–
12.25; q5 C 12.25), and C-reactive protein
(CRP) (mg/L: q1 B 2.26; q2= 2.26–4.14;
q3= 4.14–7.21; q4 = 7.21–14; q5 C 14).
Table 1 Studies, countries and hemoglobin target ranges included in the pooled analysis






ML21040 NCT00642850 Czech Republic 155 (7.5) 10.0–12.0 Lower
ML21145 NCT00717821 France 225 (10.9) 10.0–12.0 Lower
ML20752 NCT00660023 Hungary 107 (5.2) 10.0–12.0 Lower
ML21438 NCT00699348 Italy 298 (14.5) 10.0–12.0 Lower
ML21060 NCT00605293 Spain 48 (2.3) 10.0–12.0 Lower
ML21096 NCT00661505 Turkey 102 (5.0) 10.0–12.0 Lower
ML21208 NCT00560404 Brazil 76 (3.7) 10.5–12.5 Upper
ML20952 NCT00550680 Greece 152 (7.4) 10.5–12.5 Upper
ML20881 NCT00517413 Latin America 129 (6.3) 10.5–12.5 Upper
ML21797 NCT00882713 Morocco 182 (8.8) 10.5–12.5 Upper
ML20977 NCT00576303 Russia 178 (8.6) 10.5–12.5 Upper
ML20572 NCT00413894 Germany 344 (16.7) 11.0–12.5 Upper
ML20826 NCT00545571 Switzerland 64 (3.1) 11.0–13.0 Upper
Individual study results are summarized as supporting information (Supplementary Table 1) and accessible on http://www.
roche-trials.com
Fig. 1 Common study design. In all 13 studies, enrolled
patients entered a 4- to 8-week screening period followed by
a 16-week C.E.R.A. dose-titration period, and an 8-week
evaluation period. C.E.R.A. continuous erythropoietin
receptor activator, ESA erythropoiesis-stimulating agents
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Study Treatment
Patients continued to receive epoetin or
darbepoetin during screening, with no dose
interval changes. C.E.R.A. (Micera, F.
Hoffmann-La Roche Ltd., Basel, Switzerland)
was administered during dose titration and
evaluation. The starting C.E.R.A. dose was based
on the last dose of previous ESA, according to the
Summary of Product Characteristics: \8000
international units (IU) epoetin or \40 lg
darbepoetin alfa = 120 lg (or 125 lg in study
ML20572) C.E.R.A.; 8000–16,000 IU epoetin
or 40–80 lg darbepoetin alfa = 200 lg C.E.R.A.;
[16,000 IU epoetin or [80 lg darbepoetin
alfa = 360 lg C.E.R.A. [18].
C.E.R.A. doses were adjusted during titration
and evaluation at the investigator’s discretion
to maintain Hb within the pre-defined target
range of each individual study.
Efficacy and Safety Comparisons
in Defined Subgroups
Efficacy endpoints were Hb concentration, Hb
fluctuation, proportion of patients maintaining
Hb stability (Hb concentration change B1.0 g/dL
from screening to evaluation period or
maintained within the target range), required
dose of C.E.R.A. and dose adjustments.
Safety endpoints for comparative subgroup
analyses were the number of adverse events
(AEs) and serious AEs (SAEs), cardiac events and
serious CV events, thromboembolic events
(including vascular access thrombosis),
hypertensive events (including reports of
hypertension, hypertensive crisis and blood
pressure fluctuation) and vascular disorders
(without hypertensive events) e.g., stenosis,
phlebitis, arteriosclerosis.
At each study visit, routine laboratory
measurements were conducted. Relevant tests
known to correlate with ESA response were:
transferrin saturation, ferritin, and CRP.
Additionally, an ESA resistance index was
computed: the rank of the cumulative ESA
dosing in the screening period (before switching
toC.E.R.A.)over the rankof the averageHbduring
the screening period [19, 20]. In most studies
NT-proBNP was measured at baseline.
Statistical Methods
This analysis included patients who reached the
efficacy evaluation period (intention-to-treat
completers).
Average Hb concentrations for a particular
period were based on all Hb assessments during
that period. If H0,…,Hn are taken at timepoints
t0,…,tn, the time-adjusted average Hb value per
patient (Hb concentration) was calculated by:
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Hb fluctuation was estimated by a successive









Hi Hi1ð Þ2 ti  ti1ð Þ
vuut
This fluctuation measure is less prone to
overall trends in Hb development compared
with usual standard deviation (SD) measures.
Overall Hb stability was the proportion of
patients maintaining Hb concentration within
±1.0 g/dL from the screening to the evaluation
period or staying within target range of the
pertaining study.
Differences between subgroups were tested
by t tests or Wilcoxon rank sum tests for metric
variables or Chi-square tests for categorical
variables.
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A word of statistical caution: this study’s
database is large; therefore even small
differences between groups can become
statistically significant. Differences should be
judged by their relative size and potential
clinical relevance, not by formal statistical
significance. In order to avoid spurious




In total, 2060 patients [mean (SD) age 60.6
(15.6) years, 57.6% male] from 13 studies were
included in the analysis. Demographic and
baseline characteristics are summarized in
Table 2. The largest renal disease etiology
subgroups were hypertension [n = 487 (28%)],
diabetes [n = 351 (21%)] and
glomerulonephritis [n = 318 (19%)]
(percentages based on patients with defined
etiology). In total, 1508 patients (73%) had C1
prior disease/risk factor, the most common
being vascular disorders (68%) and
metabolism/nutrition disorders (38%). Most
patients (81%) received epoetin during
screening; 43% received epoetin alfa, 38%
epoetin beta, and 28% darbepoetin. Some
patients had a change in ESA medication
during the screening period, thus numbers add
to over 100%.
Patients were divided into subgroups as
follows: lower/upper Hb target range (n = 935/
n = 1125); male/female (n = 1186/n = 874);
\65/C65 years (n = 1090/n = 932); low/high
baseline NT-proBNP (n = 975/n = 624);
patients with diabetes (n = 535), with cardiac
risk factors (n = 565), with vascular risk factors
(n = 1675), with no CV risk factors (n = 283).
Table 2 Demographic characteristics of patients
(n = 2060)
Male, n (%) 1186
(57.6)
Mean age, years ± SD 61 ± 15.6
Mean weight, kg ± SD 71 ± 15.2
Mean height, cm ± SD 166 ± 9.7
Ethnicity, n (%)
White 1533 (74)




Etiology of renal disease, n (%)
Hypertension/large vessel disease 487 (28)
Glomerulonephritis 318 (19)
Diabetes 351 (21)
Interstitial nephritis/pyelonephritis 217 (13)
Polycystic kidney disease 109 (6)
Sec. glomerulonephritis/vasculitis 56 (3)
Other hereditary/congenital diseases 35 (2)
Neoplasms/tumors 34 (2)
Other 160 (9)
Undeﬁned etiology 315 (18)
Prior diseases/risk factors
Vascular disorders 1397 (68)
Metabolism and nutrition disorders 778 (38)
Cardiac disorders 390 (19)
Surgical and medical procedures 317 (15)
Nervous system disorders 151 (7)
Gastrointestinal disorders 110 (5)
Infections and infestations 29 (1)
Respiratory, thoracic and mediastinal
disorders
19 (1)
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Efficacy
As seen previously [6, 7], the overall population
achieved stable Hb concentrations throughout
screening, titration and evaluation periods, and
exhibited Hb fluctuations *0.5 g/dL during
evaluation. The mean Hb level was 11.4 g/dL
during both screening and evaluation and was
11.7 g/dL during titration. A high proportion of
patients exhibited Hb stability (Hb
concentration within ±1 g/dL from screening
or within the target range) (Fig. 2). Overall,
patients required an average C.E.R.A. dose of
133.4 lg during titration and 131.3 lg during
evaluation. During titration, patients received
8220 C.E.R.A. administrations in total; dose
changes were required in 3078 cases (37.4%).
During the evaluation period, patients received
a total of 4103 doses; dose changes were
required in 737 cases (18.0%). Efficacy within
different subgroups during the evaluation
period is considered in detail below.
Hemoglobin Target Range
Mean achieved Hb in the lower and upper Hb
target groups differed by 0.4 g/dL (11.2 vs 11.6;
p\0.0001) (Table 3; Fig. 3). Hb fluctuations
were also higher in the upper Hb group (0.46
vs 0.50; p = 0.001) (Table 3), whereas Hb
stability or dose changes did not differ
significantly between target range groups.
Table 2 continued





ESA erythropoiesis-stimulating agent, SD Standard
deviation
Fig. 2 Proportion of patients exhibiting hemoglobin
stability. Across all studied subgroups, a large majority
of patients (76–80%) exhibited hemoglobin stability
(hemoglobin concentration within ±1 g/dL from screening
or within the target range, evaluation period). CV
cardiovascular, L lower, NT-proBNP N-terminal
pro-B-type natriuretic peptide, U upper
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Patients with lower target Hb range required
significantly lower C.E.R.A. doses than the
upper Hb target subgroup (124.7 vs 136.9 lg;
p\0.001) (Table 3). Iron status and CRP values
were not significantly different in the two Hb
target groups; they were slightly more favorable
in the upper group (data not shown). ESA
resistance index and baseline NT-proBNP were
also closer to normal values in the upper target
group than in the lower: median TSAT 28.8% vs
27.5% (p = 0.05); median ferritin 456.5 vs
465.0 lg/L (p = 0.43); median CRP 4.4 vs
4.7 mg/L (p = 0.22); median ESA resistance
index 0.8 vs 1.4 (p\0.001); median
NT-proBNP (pg/mL) 2982 vs 4047 (p\0.001).
Gender
All efficacy outcomes were similar across male
and female subgroups (Table 3).
Age
Achieved Hb concentrations, Hb stability, dose
changes required, or C.E.R.A. dose required
were not significantly different in patients


















All 2060 11.4 0.48 78 131.3 18.0 0.4
Target group
L
935 11.2 0.46 80 124.7 19.1 0.4
Target group
U
1125 11.6 0.50b 77 136.9b 17.1 0.3
Female 874 11.4 0.48 80 131.0 17.2 0.3
Male 1186 11.5 0.48 77 131.6 18.5 0.4
Age\65 1090 11.5 0.5 77 131.5 18.4 0.4
Age C65 932 11.4 0.45a 80 129.3 17.5 0.4
NT-proBNP
\5000
975e 11.4 0.47 78 124.3 18.1 0.4
NT-proBNP
C5000
624e 11.4 0.49 80 138.0c 18.2 0.4
No CV risk 283 11.5 0.51 78 127.8 17.7 0.4
Cardiac risk 565 11.4 0.46d 78 136.2 18.0 0.4
Vascular risk 1675 11.4 0.48 79 132.2 18.1 0.4
Diabetes at
baseline
535 11.3 0.47 76 132.5 17.4 0.3
Italicized values indicate signiﬁcant differences (p\0.01) between subgroups: a p\0.001; b p = 0.001; c p = 0.002;
d p = 0.01
e NT-proBNP was not measured for all patients
CV cardiovascular, L lower, NT-proBNP N-terminal pro-B-type natriuretic peptide, U upper
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aged C65 years and those \65 years (Table 3).
However, Hb fluctuation values were
significantly higher in patients aged\65 years
(0.51 vs 0.45 g/dL; p\0.001) (Table 3).
Baseline NT-proBNP Levels
Patients in the high and low NT-proBNP
subgroups did not have significantly different
Hb concentrations, Hb fluctuation, Hb stability
or required dose changes (Table 3). However,
those in the low NT-proBNP group required
significantly lower C.E.R.A. doses than those in
the high group (124.3 vs 138.0 lg; p = 0.002)
(Table 3). The iron status was slightly higher in
the low NT-proBNP subgroup than in the high
subgroup, while CRP values and ESA resistance
index were significantly lower (more favorable)
in the low NT-proBNP group than in the high
group (Table 4).
Cardiovascular Risk Factors
Achieved Hb concentrations, Hb stability,
required C.E.R.A. dose and dose changes were
not significantly different in patients with
Fig. 3 Mean Hb levels over time, by target Hb group. The error bars show 95% conﬁdence intervals. In the upper (square
symbols) and the lower (triangle symbols) Hb target groups, the achieved Hb levels were stable over time. Hb hemoglobin
Table 4 Median TSAT, ferritin, CRP and ESA resistance index in subgroups according to NT-proNBP levels high
([5000 ng/mL) or low (B5000 ng/mL)





TSAT, % 29.8 28.2 0.05
Ferritin, lg/L 430.0 470.0 0.11
CRP, mg/L 4.0 5.0 0.003
ESA resistance index 1.1 1.3 \0.001
Italicized values indicate signiﬁcant differences (p\0.01) between subgroups
CV cardiovascular, CRP C-reactive protein, ESA erythropoiesis-stimulating agent, NT-proBNP N-terminal pro-B-type
natriuretic peptide, TSAT transferrin saturation
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pre-existing CV risk factors and patients with
no CV risk factors (Table 3). Hb fluctuation
values were significantly different between
those with pre-existing cardiac risk factors
and those without CV risk factors (0.46 vs
0.51 g/dL; p = 0.01) (Table 3). Furthermore, a
trend towards lower dose requirements in the
group with no CV risk factors was observed.
TSAT values were slightly favorable for the no
CV risk group compared with patients with
diabetes, cardiac or vascular complications,
whereas the opposite was seen for ferritin
(Table 5). Likewise, CRP values were lower for
the no CV risk group compared with those
with diabetes, cardiac or vascular
complications, while a higher resistance index
was seen in the no CV risk group (Table 5).
Baseline NT-proBNP levels were significantly
lower in the no CV risk group compared with
the other subgroups (Table 5).
Safety
Overall safety results from individual studies
have been reported in the respective
publications and study reports. This section
focusses on differences in safety outcomes
between analyzed patient subgroups.
Compared with patients aged \65 years,
those aged C65 years experienced higher
incidences of AEs (59.4% vs 72.0%, p\0.001),
SAEs (20.0% vs 30.8%, p\0.001), cardiac AEs
(4.7% vs 8.7%, p\0.001) and thromboembolic
AEs (1.3% vs 3.4%, p = 0.003) (Table 6). Patients
with a baseline NT-proBNP level C5000
experienced higher AE incidences compared
with those in the low NT-proBNP group,
including all AEs (59.1% vs 65.9%, p = 0.007),
SAEs (19.4% vs 27.4%, p\0.001), cardiac AEs
(3.3% vs 9.0%, p\0.001) and serious CV AEs
(2.5% vs 5.3%, p\0.005) (Table 6). Overall,
patients with pre-existing risk factors also
experienced higher AE incidences compared
with patients with no CV risk factors (Table 6).
In the twohighestC.E.R.A.dosequintiles, and
in the two lowestHbquintiles, a slight increase in
the rate of cardiac AEs was observed (Fig. 4). In
the highest dose group, the percentage of
patients experiencing serious CV AEs (6.3%),
thromboembolic AEs (5.1%), and vascular AEs
(2.4%) was higher than in all other dose
quintiles. Contrastingly, similar frequencies of
serious CV, thromboembolic and vascular AEs
were recorded across the first four Hb quintiles,
and lowest values were observed in the fifth
quintile; thus, therewas no relationship between





p value Cardiac risk
factors
n 5 565




TSAT, % 29.6 27.1 0.008 26.5 \0.001 28.1 0.02
Ferritin, lg/L 428.5 494.0 0.05 487.9 0.005 465 0.07
CRP, mg/L 4.0 5.0 0.1 5.1 0.03 4.6 0.51
ESA resistance index 1.2 1.0 0.02 0.9 \0.001 1.0 0.04
NT-proNBP, pg/mL 2544 3463 \0.001 5477 \0.001 3753 \0.001
Italicized values indicate signiﬁcant differences (p B 0.01) between subgroups (risk group versus no CV risk)
CV cardiovascular, CRP C-reactive protein, ESA erythropoiesis-stimulating agent, NT-proBNP N-terminal pro-B-type
natriuretic peptide, TSAT transferrin saturation
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Hb level and rate of CV AEs. Finally, high CRP
levels appear to be associated with increased
serious, thromboembolic and vascular AEs:
thromboembolic AEs occurred in 5.0% of
patients in the two highest quintiles compared
with 3.2% in the other quintiles, with a similar
pattern seen for serious AEs (3.9% vs 2.2%) and
vascular AEs (2.3% vs 1.1%).
DISCUSSION
This retrospective analysis of 13 trials included
in the Phase III C.E.R.A. clinical program
evaluated the efficacy and safety of C.E.R.A. in
clinically relevant patient subgroups of patients
with CKD on hemodialysis, confirming and
extending the findings of an earlier poster




















All 2060 65 24.9 6.5 3.9 2.9 7.7 1.6
Target Group
L
935 66.5 24.9 5.9 4.2 2.9 8.1 2.3
Target Group
U
1125 63.7 22.4 6.9 3.7 2.9 7.3 1.1
Female 874 66.1 25.7 5.8 3.7 2.7 7.9 1.8
Male 1186 64.2 24.2 6.9 4.1 3.0 7.5 1.4
Age\65 1090 59.4 20.0 4.7 3.5 1.3 7.7 1.6
Age C65 932 72.0a 30.8a 8.7a 4.4 3.4b 7.6 1.6
NT-proBNP
\5000
975f 59.1 19.4 3.3 2.5 2.5 6.9 1.1
NT-proBNP
C5000
624f 65.9d 27.4a 9.0a 5.3c 3.0 9.6 2.2
No CV risk 283 45.9 17.0 2.1 1.4 2.5 2.8 0.0
Cardiac risk 565 71.7e 34.4e 11.0e 6.2e 4.4e 8.9e 2.5e
Vascular
risk
1675 64.3e 26.4e 7.1e 4.5e 2.9e 8.7e 2.0
Diabetes at
baseline
535 71.2e 33.6e 7.3e 5.4e 5.4e 6.4e 2.1
Italicized values represent differences (p\0.01) between subgroups: a p\0.001; b p\0.003; c p\0.005; d p = 0.007;
e p\0.01. For cardiac risk, vascular risk and diabetes at baseline the comparison is with no CV risk
f NT-proBNP was not measured for all patients
AE adverse event, CV cardiovascular, L lower, NT-proBNP N-terminal pro-B-type natriuretic peptide, SAE serious AE,
U upper
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presentation of some of these subgroups [22]
and an earlier pooled analysis of safety in both
dialysis and non-dialysis patients, which
concluded that C.E.R.A. showed an overall
safety profile comparable with other ESAs [21].
In the current analysis, C.E.R.A. QMmaintained
stable Hb concentrations uniformly across all
subgroups considered, including those with
elevated risk profiles.
The Phase III program included numerous
trials of similar design, allowing pooled analysis
of results, but the limitations of such an
approach should be recognized. All of the
analyses were of single arms without a
comparator group. While the trials were
designed within the same framework as part of
an umbrella program, they were performed in
different countries and were by no means
identical. The post hoc nature of the analysis
is also an important limitation, as comparisons
were neither pre-planned nor suitably powered
to determine significant efficacy and safety
differences between subgroups.
Most significant differences between
subgroups were numerically small and may
not be clinically relevant. The proportion of
patients demonstrating Hb stability was similar
across all subgroups, with the lowest value
Fig. 4 Percentage of patients with CV AEs per dose, Hb
and CRP quintile. The proportion of patients experiencing
cardiac, serious CV, thromboembolic, and vascular AEs is
shown by quintiles of Hb, C.E.R.A. dose and CRP. AE
adverse event, C.E.R.A. continuous erythropoietin receptor
activator, CRP C-reactive protein, CV cardiovascular, Hb
hemoglobin
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(76%) in patients with diabetes. Mean Hb
fluctuations were around 0.5 g/dL across all
subgroups, independent of Hb target, gender
and pre-existing CV risk factors.
The favorable efficacy, safety and tolerability
profile of C.E.R.A. in the general CKD
population had been reported previously
[7–12, 15, 16]. The impact of low Hb on
mortality and CV morbidity was demonstrated
in retrospective analyses of nine Phase III,
randomized, controlled trials involving 3405
patients with anemic CKD treated with C.E.R.A.
[23]. In these analyses, average Hb level\10 g/dL,
decrease from stable baseline Hb[1 g/dL, last Hb
level\10 g/dL, Hb decline[1.5 g/dL/4 weeks and
increased Hb variability were associated with a
higher risk of the composite endpoint and
all-cause mortality.
In our analysis, despite stable Hb
maintenance across patient subgroups, there
were notable differences in the C.E.R.A. dose
required. As expected, patients in the upper Hb
target group required higher doses than those in
the lower target group; however, the mean
value required for the upper Hb target group
(136.9 lg) was relatively low despite the
difference being statistically significant. Iron
status, CRP, NT-proBNP and ESA resistance
index were comparable between subgroups or
closer to adequate in the upper target group
than the lower, suggesting that dose
requirement differences were due to varying
target ranges rather than deficiency in
ESA-response background variables. The higher
doses needed in the high NT-proBNP group
compared with the low subgroup may be due to
volume overload, hemodilution or underlying
diseases such as chronic cardiac congestive
failure [24, 25]. Indeed, high NT-proBNP levels
are thought to result from the inflammatory
process consequent to cardiac diseases and
impaired renal function [25]. Iron status was
comparable between the two NT-proBNP
groups; however, CRP and ESA resistance
index were slightly lower in the low group.
Whether these differences can explain the
variation in required dose in the two
subgroups is uncertain: chronic cardiac
congestive failure would not correlate strongly
with CRP or iron status. Notably, the proportion
of C.E.R.A. dose modifications required was low
to moderate across all subgroups.
We acknowledge that caution should be
taken when interpreting statistically significant
figures that lack clinical plausibility. Likewise,
non-significant differences do not provide
categorical proof that no difference exists
between subgroups. For example, the
non-significant trend towards lower dose
requirements in no-CV risk patients is
supported by elevated NT-proBNP levels in
patients with pre-existing CV risk factors,
reinforcing the observation that NT-proBNP
levels may be predictive for higher C.E.R.A.
dose requirements.
Safety outcomes were as expected across
subgroups. Neither Hb target range nor gender
influenced the incidence of AEs; however, all
AEs, SAEs, cardiac AEs and serious CV AEs were
significantly higher in patients with underlying
risk factors (older age, high NT-proBNP or
pre-existing CV risk factors) compared with
their lower risk counterparts. Non-significant
differences in the incidences of
thromboembolic and vascular AEs were also
observed between subgroups. Observations in
the NT-proBNP subgroups are supported by a
recent analysis in end-stage renal disease
patients on dialysis, where high baseline
NT-proBNP levels predicted higher incidences
of cardiac and CV endpoints (5000 ng/mL) [17].
Moreover, elevated NT-proBNP levels have been
revealed as an independent mortality predictor
in incident hemodialysis patients [25]. While
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baseline NT-proBNP level was not predictive for
hypertensive AEs, pre-existing CV risk factors
were. Overall, the increase in CV AEs
experienced with pre-existing CV risk factors
suggests AEs were not related to C.E.R.A.
administration.
CV AEs of interest were analyzed by quintiles
of Hb, C.E.R.A. dose and CRP. A slight increase
in AE rates was observed in the quintiles with
lowest Hb levels and highest doses. These
findings agree with previous observations and
clinical guidelines that recommend
conservative Hb targets (10–12 g/dL),
individualized for each patient’s comorbidities.
If ESA therapy is used in patients
hyporesponsive to ESA treatment, aiming
towards the lower Hb levels of the target range
is recommended [3, 26].
Furthermore, our data showed that chronic
elevation of CRP levels was associated with
increased thromboembolic and vascular AEs.
This agrees with previous observations that
suggest CRP—a marker of inflammation—
constitutes an independent risk factor for CV
disease [27]. Caution should be used in patients
hyporesponsive to ESA treatment having high
CRP levels or in those with specific risk factors
(especially diabetics) or conditions such as
symptomatic limb arteriopathy, stroke or
non-symptomatic ischemic heart disease, or
cancer [27].
CONCLUSION
C.E.R.A. QM maintained stable Hb
concentrations with moderate fluctuations
across subgroups of patients with chronic
renal anemia on dialysis switching from
maintenance therapy with shorter-acting ESAs,
including those with underlying risk factors.
Differences in required C.E.R.A. doses were
observed between patients with upper and
lower Hb target levels, and with high and low
baseline NT-proBNP levels. The safety profile
across subgroups was as expected based on
pre-existing risk factors; any increases in AEs
were related to underlying risk factors rather
than to the study drug.
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